Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 51, pp. 85573 - 85583
Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real...
Efficacy | Bendamustine | Safety | Peripheral T cell lymphoma | GUIDELINES | NON-HODGKINS-LYMPHOMAS | BRENTUXIMAB VEDOTIN | PHASE-II | CLASSIFICATION | efficacy | TRANSPLANTATION | CELL BIOLOGY | SINGLE-AGENT | THERAPY | CHEMOTHERAPY REGIMENS | ONCOLOGY | safety | peripheral T cell lymphoma | OUTCOMES | bendamustine | Multivariate Analysis | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents, Alkylating - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | Retrospective Studies | France | Odds Ratio | Lymphoma, T-Cell, Peripheral - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Lymphatic Metastasis | Disease Progression | Disease-Free Survival | Lymphoma, T-Cell, Peripheral - pathology | Aged | Antineoplastic Agents, Alkylating - adverse effects | Lymphoma, T-Cell, Peripheral - mortality | Life Sciences | Cancer
Efficacy | Bendamustine | Safety | Peripheral T cell lymphoma | GUIDELINES | NON-HODGKINS-LYMPHOMAS | BRENTUXIMAB VEDOTIN | PHASE-II | CLASSIFICATION | efficacy | TRANSPLANTATION | CELL BIOLOGY | SINGLE-AGENT | THERAPY | CHEMOTHERAPY REGIMENS | ONCOLOGY | safety | peripheral T cell lymphoma | OUTCOMES | bendamustine | Multivariate Analysis | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents, Alkylating - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | Retrospective Studies | France | Odds Ratio | Lymphoma, T-Cell, Peripheral - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Lymphatic Metastasis | Disease Progression | Disease-Free Survival | Lymphoma, T-Cell, Peripheral - pathology | Aged | Antineoplastic Agents, Alkylating - adverse effects | Lymphoma, T-Cell, Peripheral - mortality | Life Sciences | Cancer
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.